Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuroblastoma & CCHS Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PHOX2B drug discovery. As a nuclear transcription factor driving neuroblastoma malignancy and CCHS pathogenesis, PHOX2B requires specialized intracellular targeting strategies. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | PHOX2B Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. Suitable for EMSA, DNA-binding, and PPI assays. |
View PHOX2B Products |
| Mutant Antigen | PHOX2B Polyalanine Expansion Mutant (20-Ala / 25-Ala / 27-Ala) CCHS-associated variants, High Purity (>95%). For disease mechanism modeling. |
View PHOX2B Products |
| Gene Delivery | PHOX2B Lentivirus Particles Full-length ORF for stable cell line generation in neuroblastoma models (SH-SY5Y, IMR-32). Endotoxin controlled. |
View PHOX2B Products |
| Benchmark Ab | Anti-PHOX2B (Homeodomain Specific) ChIP-grade recombinant antibody for Western/IP validation. |
View PHOX2B Products |
| Validator | PHOX2B siRNA Set For transcription factor knockdown validation and specificity controls. |
View PHOX2B Products |
| Related Target A | HLA-A MHC Class I component crucial for PHOX2B peptide presentation to TCR-T/CAR-T cells. |
View HLA-A Products |
| Related Target B | ALK Receptor tyrosine kinase; mutated/amplified in subset of neuroblastomas; rational combination target. |
View ALK Products |
| Related Target C | MYCN Oncogenic driver frequently co-amplified with PHOX2B in high-risk neuroblastoma. |
View MYCN Products |
| Related Target D | PHOX2A Paralogous transcription factor; potential compensatory mechanism and off-target liability. |
View PHOX2A Products |
| Related Target E | HAND2 Direct interactor in sympathetic differentiation; PPI assay partner. |
View HAND2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Presentation (CAR-T/Cell-penetrating validation) | Full-length PHOX2B protein with native conformation; Sequence verified for HLA-presentation prediction assays. |
| DNA-Binding Specificity & Affinity | High-purity recombinant protein (>95%) for EMSA and SPR-based DNA consensus sequence binding studies. |
| CCHS Mutant Phenotype Modeling | Polyalanine expansion mutants (20-Ala, 25-Ala, 27-Ala) vs WT strictly purified for comparative functional assays. |
| Paralog Selectivity (PHOX2A vs PHOX2B) | Homolog panel (PHOX2A, PHOX2B) with distinct epitope mapping for cross-reactivity screening. |
| High-Background False Positives | Sequence-verified, high-purity (>95%) recombinant proteins ensure precise assay baselines without contaminant interference. |
| Lack of Validated Controls | PHOX2B-specific siRNA and overexpression lentivirus included for loss/gain-of-function validation. |
Live PHOX2B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Neuroblastoma Research
- CCHS Resistance Mechanisms
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for PHOX2B therapeutics is intensifying. As a nuclear transcription factor highly expressed in neuroblastoma and mutated in CCHS, PHOX2B was traditionally considered "undruggable." The breakthrough relies on targeting PHOX2B-derived peptides presented on the cell surface by HLA molecules, primarily HLA-A*24:02. Major players like Myeloid Therapeutics, CHOP, MSKCC, and Bay Area Pediatric Consortium are advancing TCR-mimic CAR-T and TCR-T therapies into Phase I/II trials for relapsed/refractory neuroblastoma. Simultaneously, antisense oligonucleotides (ASOs) from Ionis Pharmaceuticals and Biogen aim to correct polyalanine expansion mutations in CCHS. Emerging modalities include targeted protein degradation (PROTAC/molecular glue) and allosteric inhibitors disrupting PHOX2B-HAND2 protein-protein interaction. The next wave of R&D targets enhanced affinity tuning to prevent cross-reactivity, optimization of T-cell engager bispecifics, and transcriptional complex modulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T / TCR-T (Peptide-targeted) | Myeloid Therapeutics, CHOP, MSKCC, Bay Area Pediatric Consortium | Relapsed/Refractory Neuroblastoma | Antigen Presentation Assay (Need PHOX2B Lentivirus for cell lines & recombinant protein for epitope mapping) |
| T-Cell Engagers (Bispecifics) | Preclinical Biotech Innovators | Pediatric Solid Tumors | Selectivity Screening (Need High-Purity PHOX2B Protein and HLA controls) |
| ASO / Gene Therapy | Ionis Pharmaceuticals, Biogen; Rare disease consortiums | Congenital Central Hypoventilation Syndrome (CCHS) | Mutant vs WT Protein Level Quantification (Need mutant-specific protein standards) |
| Targeted Protein Degradation (PROTAC) | Academic Consortia | Refractory Neuroblastoma; Solid Tumors | Protein Stability Assay (Need high-purity PHOX2B for ternary complex formation) |
| Small Molecule (DNA-binding/PPI inhibitor) | Early Discovery Biotech | Neuroblastoma | DNA-Binding Competition Assay (Need native full-length protein for EMSA/SPR) |